PTU - Polskie Towarzystwo Urologiczne
list of articles:

Palliative interferon a 2b treatment of patients with malignaent renal neoplasms with metastases. Preliminary report.
Article published in Urologia Polska 1996/49/2.


Teresa Kardel-Mizerska, Andrzej Sikorski, Grażyna Cieślińska-Wilk
Z Kliniki Urologii PAM
Kierownik: dr hab. med. A.Sikorski
i z II Zakładu Diagnostyki Rentgenowskiej PAM
Kierownik; dr hab. med. G.Cieślińska-Wilk


kidney metastases interferon a 2b.


Objcctive: Influence of Interferone alfa 2b (Intron A) on the patients with matastatic
renal carcinoma after nephrectomy.
Patients and metod: All the 10 treated patients were found to have lung and lympho-
nodes metastases. In 4 the remaining kidney was involved, in 4 - liver metastases were
found, 6 had osseous metastases and 3 - local recurrence. The patients rcceivcd interfe-
rone alfa 2b in subcutancous injections, twice a weck, cvery 10 weeks in a dose of 3 x
It)6 TU.
5 patients had 1 cycle of therapy, 3-2 cycle and 2-3 cycle.
Results: In 2 patients partial remission had been found lasting for one year, in 3-
stabilization of the disease for 5-8 months. Improvemcnt in general condition according
to Karnofsky scale was found in all treated patients after completing the first cycle of
Flu-like symptoms were the common side-effect in all the patients.
Conclusion: Will be presented after completing the study.


  1. 1. Ahi-AadA., Belldegrun A.: Renal cell carcinoma: physiology, diagnosis and therapy.
  2. World J.Urol., 1991, 9, 168.
  3. 2. Bergmann L., Weidmann E.: Intcrleukin-2 and interferon 2b as a daily altcrnating
  4. schedule in advanced renal cell cancer. World J.Urol., 1991, 9, 215.
  5. 3. Blach-OIszewska Z: Interferony i ich znaczenie dla organizmu. Biologiczne aktyw-
  6. ności interferonów. Postępy Hig.Med.Dośw., 1988, 42, 260.
  7. 4. Fossa S., Stewing A.: Long-term results in patients with metastatic renal cell carcino-
  8. ma treated with interferon with or without vinblastine. World J.Urol., 1991, 9, 210.
  9. 5 Goepoel M., Rubben M.\ Adjuyant therapy in renal cancer. World JJLJrol., 1991, 0,
  10. 232.
  11. 6. Heicapel R., Ackermann R.\ Current strategies for iminunotherapy of renal cell car-
  12. cicoma. World J.Urol., 1991, 9, 204.
  13. 7. Kirchner II, de Riese W., Allkoff E.: Immunotherapy of advanced renal cell cancer
  14. using subcutancous rccombinant interleukin-2 and interferon. World J.Urol., 1991,
  15. 9, 219.
  16. 8. Kriegmair M.\ Interferon therapy in urology. Urologe, 1989, 28, 116.
  17. 9. Ma rum o K., Murai A/., Tazaki H.: Human lymphoblastoid interferon therapy for ad-
  18. vanced renal cell carcicoma. Urology, 1984, 6, 567.
  19. 10. Ncidhan'./., Gagen M, Young D., Tuttle R.: Interferon alpha therapy of renal cancer.
  20. Cancer Res., 1984,44, 4140.
  21. 11. Tntmp D-, Elson R, Borden E., Harris E:. High-dose lymphoblastoid interferon in
  22. advanced renal cell carcicoma. Cancer Treat., 1987, 2, 165.
  23. 12. Vugrin D., Hood L., Łaszka ./.: A phase 11 trial of high-dose human lymphoblastoid
  24. alpha interferon in patients with advanced renal carcicoma. J.Biol.Resp,, 1986, 4, 309.